1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Most well-differentiated neuroendocrine tumors (WD-NET) of the enteropancreatic system are low-intermediate grade (G1, G2). Elevated proliferation demonstrated by either a brisk mitotic rate (>20/10 high power fields) or high Ki-67 index (>20%) defines a group of aggressive neoplasms designated as high-grade (G3) neuroendocrine carcinoma (NEC). High-grade NEC is equated with poorly differentiated NEC (PD-NEC) and is associated with a dismal outcome. Progression of WD-NETs to a high-grade neuroendocrine neoplasm very rarely occurs and their clinicopathologic and molecular features need to be characterized.

          Related collections

          Author and article information

          Journal
          Clin. Cancer Res.
          Clinical cancer research : an official journal of the American Association for Cancer Research
          American Association for Cancer Research (AACR)
          1078-0432
          1078-0432
          Feb 15 2016
          : 22
          : 4
          Affiliations
          [1 ] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. tangl@mskcc.org.
          [2 ] Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
          [3 ] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
          [4 ] Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California.
          [5 ] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
          Article
          1078-0432.CCR-15-0548 NIHMS791689
          10.1158/1078-0432.CCR-15-0548
          4988130
          26482044
          a79a91c0-a282-4890-952f-09f1946f603d
          History

          Comments

          Comment on this article